0911 (0911) Fair Value & Analysis

Healthcare · Market cap HK$108M

0 0911 0911 · HK

PriceHK$0.6400

Fair ValueHK$0.8900

Upside+39.1%

Quality69/100

Evidence: High Range HK$0.6300 – HK$0.9600

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −14.7% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.2240 – HK$1.20 · fair‑value band HK$0.6300 – HK$0.9600 · the HK$0.6400 price screens below the HK$0.8900 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0911 (0911) currently trades at HK$0.6400, while our model-based Fair Value estimate is HK$0.8900 — implying the stock looks roughly 39.1% undervalued today. We read business quality at 69/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 0911 generated revenue of HK$677M at a net margin of 0.9%. Revenue grew 58.1% year over year. It earns a return on equity of 1.5%. The balance sheet holds a net cash position of HK$61.0M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$677M

Revenue growth (YoY) +58.1%

Net margin 0.9%

Return on equity 1.5%

Free cash flow HK$38.8M FY2025

P/E ratio 16.0

More key figures

Operating margin 0.3%

EPS (TTM) HK$0.0300

EPS growth (YoY) -69.3%

Net cash HK$61.0M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0911 reported revenue of HK$677M in FY2025 versus HK$283M in FY2021, a compound +24.3%/yr. Reported net income was HK$5.9M in FY2025.

Revenue +24.3%/yr

FY21 HK$283M

FY22 HK$2.0B

FY23 HK$961M

FY24 HK$520M

FY25 HK$677M

Net income

FY21 −HK$888K

FY22 −HK$234M

FY23 −HK$52.7M

FY24 HK$1.3M

FY25 HK$5.9M

Is 0911 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.01	¥26.59	-43%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.58	HK$18.75	-37%
Divi's Laboratories Limited DIVISLAB	₹6,788	₹2,035	-70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0911 (0911) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.8900 versus a price of HK$0.6400 — about +39% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 0911?

Our model-based fair value for 0911 is HK$0.8900 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.6400.

What is the quality score of 0911?

0911 has a Quality Score of 69/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0911 (0911)?

0911 reported trailing-twelve-month revenue of about HK$677M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0911?

The net profit margin of 0911 is about 0.9%, meaning it keeps roughly 0.9% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.